EUVIMEDEUVIMED entdecken
Crossref

The Impact of Health Technology Assessment on Pharmaceutical Prices: Evidence from Germany

Giovanni Righetti

The European Journal of Health Economics · 25.04.2026

DOI: 10.1007/s10198-026-01924-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The European Journal of Health Economics, online erschienen am 25.04.2026. Verfasst von Giovanni Righetti. Beteiligte Einrichtung: Department of Economics, University of Verona, Via dell'Artigliere 8, Verona, 37129, Italy. giovanni.righetti@univr.it. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In years of growing pharmaceutical expenditures, many European countries have adopted Health Technology Assessment (HTA) frameworks to align drug prices with clinical value. Germany’s 2011 AMNOG reform introduced mandatory price negotiations for new medicines, based on their added therapeutic benefit. This paper estimates the causal impact of AMNOG on anticancer drug prices using a triple-difference approach and a panel of 77 drugs launched between 2007 and 2017 across 24 OECD countries. The reform led to a 15.8% reduction in post-negotiation prices in Germany, and there is no evidence that manufacturers raised launch prices strategically in anticipation of future negotiated reductions. These findings confirm the effectiveness of HTA-based pricing mechanisms and contribute to ongoing policy discussions on sustainable pharmaceutical pricing in Europe.

Schlagwörter

Stichwörter der Autor:innen

AMNOGHealth technology assessmentPharmaceutical regulationTriple differences

Autor:innen und Institutionen

  • Department of Economics, University of Verona, Via dell'Artigliere 8, Verona, 37129, Italy. giovanni.righetti@univr.it.

Zitieren

APA

Righetti, G. (2026). The Impact of Health Technology Assessment on Pharmaceutical Prices: Evidence from Germany. The European Journal of Health Economics. https://doi.org/10.1007/s10198-026-01924-5

Vancouver

Righetti G. The Impact of Health Technology Assessment on Pharmaceutical Prices: Evidence from Germany. The European Journal of Health Economics. 2026. doi:10.1007/s10198-026-01924-5

BibTeX
@article{Righetti2026,
  author = {Righetti, Giovanni},
  title = {The Impact of Health Technology Assessment on Pharmaceutical Prices: Evidence from Germany},
  journal = {The European Journal of Health Economics},
  year = {2026},
  doi = {10.1007/s10198-026-01924-5}
}
Kostenlos starten →